Health Tirzepatide Shows Cardiorenal Benefit vs. Dulaglutide in Type 2 Diabetes by Grace Chen March 29, 2026 written by Grace Chen March 29, 2026 54 Worth a lookctDNA Predicts Poorer Survival Across Bladder Cancer HistologiesEbola Outbreak Caused by New Animal Transmission, Study ConfirmsMounjaro (Tirzepatide) May Lower Heart Attack Risk in Type 2 Diabetes Patients (archynewsy.com) Related 0 comments 0 FacebookTwitterPinterestEmail Grace Chen Board-certified physician and medical writer. Translates research into practical health advice and public-health coverage. previous post Dallas Daughter’s Fight: Immigrant Story & Protecting Our Future next post Trump’s Iran War Gamble: Escalation, Diplomacy & Global Oil Shock You may also like ctDNA Predicts Poorer Survival Across Bladder Cancer Histologies August 13, 2026 Ebola Outbreak Caused by New Animal Transmission, Study... August 13, 2026 HIV Market to Reach $30.6B by 2033 Driven... August 13, 2026 Review of CRISPR-enabled bacteriophage engineering and its clinical... August 13, 2026 Surrogate Gives Birth in Texas to Baby with... August 13, 2026 Cardiopedia-Ligand: Australian Researchers Launch New Heart Tissue Database August 13, 2026 Sesame Seeds: Nutritional Profile, Ancient History, and Health... August 13, 2026 Droughts and Drying Water Sources Fuel Spread of... August 13, 2026 TB Vaccine Retrains Immune System to Alter Alzheimer’s... August 13, 2026 Ebola Outbreak in DR Congo on Track to... August 13, 2026 Leave a Comment Cancel Reply Notify me of follow-up comments by email. Notify me of new posts by email. Δ
